Detection of CCR1 and CCR2 on the PB CD19+CD5+ lymphocytes could be suggested in routine diagnostic FC tests, in addition to CD38, for accurate prognosis of the high-risk progression in CLL patients at diagnosis. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.